FrancophonIA/ELRC3.0 huggingface dataset:
English: Cosentyx is used in adults with moderate to severe plaque psoriasis.
Estonian: Cosentyxi kasutatakse mõõduka kuni raske naastulise psoriaasiga täiskasvanutel.
English: • Ankylosing spondylitis
Estonian: • Anküloseeriv spondüliit
English: Non-responder imputation used for missing binary endpoint
Estonian: Puuduva binaarse tulemusnäitaja puhul kasutati ravivastuse puudumise imputatsiooni
English: • The recommended dose is 300 mg by subcutaneous injection.
Estonian: • Soovitatav annus on 300 mg nahaaluse süstena.
English: No interaction was seen when secukinumab was administered concomitantly with methotrexate (MTX) and/or corticosteroids in arthritis studies (including in patients with psoriatic arthritis and ankylosing spondylitis).
Estonian: Sekukinumabi ja metotreksaadi ja/või kortikosteroidide kooskasutamisel ei ole artriidi (sealhulgas psoriaatilise artriidi ja anküloseeriva spondüliidiga patsientidel) kliinilistes uuringutes koostoimeid täheldatud.
English: Dispose of the used syringe in a sharps container (closable, puncture-resistant container).
Estonian: Visake kasutatud süstal teravate esemete konteinerisse (suletav torkekindel konteiner).
English: ACR50 response n (%)
Estonian: ACR50 ravivastus n (%)
English: - The other ingredients are sucrose, histidine, histidine hydrochloride monohydrate and polysorbate 80.
Estonian: - Teised koostisosad on: sukroos, histidiin, histidiinvesinikkloriidmonohüdraat ja polüsorbaat 80.
English: Each 300 mg dose is given as two subcutaneous injections of 150 mg.
Estonian: Iga 300-milligrammine annus manustatakse kahe 150-milligrammise subkutaanse süstena.
English: Cosentyx is available in unit packs containing 1 or 2 pre-filled syringes and in multipacks containing 6 (3 packs of 2) pre-filled syringes.
Estonian: Cosentyx on saadaval 1 või 2 süstliga üksikpakendis ja 6 (3 pakendit 2) süstliga hulgipakendis.
English: If possible, areas of the skin that show psoriasis should be avoided as injection sites.
Estonian: Võimalusel vältida süstekohtadena nahapiirkondi, millel on psoriaasikahjustus.
English: • if you have recently had or are due to have a vaccination.
Estonian: • kui teid on hiljuti vaktsineeritud või teid vaktsineeritakse lähiajal.
English: secukinumab 300 mg (n=245)
Estonian: Sekukinumab 150 mg (n=243)
English: • The recommended dose is 150 mg by subcutaneous injection.
Estonian: • Soovitatav annus on 150 mg nahaaluse süstena.
English: After reconstitution, 1 ml of solution contains 150 mg secukinumab.
Estonian: Pärast lahustamist sisaldab 1 ml lahust 150 mg sekukinumabi.
English: Week 24 *p<0.05 based on nominal, but non adjusted, p-value 1secukinumab 150 mg or 300 mg s.c. at weeks 0, 1, 2, 3, and 4 followed by the same dose every month 10 mg/kg at weeks 0, 2 and 4 followed by subcutaneous doses of 75 mg or 150 mg
Estonian: 24. nädalal *p<0,05 nominaalse, kuid kohandamata p-väärtuse põhjal Sekukinumab 150 mg või 300 mg subkutaanselt nädalatel 0, 1, 2, 3 ja 4, millele järgnes sama annuse manustamine kord kuus
English: Patients randomised to secukinumab received 10 mg/kg intravenously at weeks 0, 2, and 4, followed by either 150 mg or 300 mg subcutaneously every month.
Estonian: Sekukinumabi rühma randomiseeritud patsiendid said 10 mg/kg veenisiseselt nädalatel 0, 2 ja 4, millele järgnes 150 mg või 300 mg subkutaanne manustamine kord kuus.
English: Cosentyx is available in unit packs containing 1 or 2 pre-filled pens and in multipacks containing 6 (3 packs of 2) pre-filled pens.
Estonian: Cosentyx on saadaval 1 või 2 pen-süstliga üksikpakendis ja 6 (3 pakendit 2) pen-süstliga hulgipakendis.
English: PASI 100 response n (%)
Estonian: PASI 100 ravivastus n (%)
English: Also contains: Sucrose, histidine, histidine hydrochloride monohydrate, polysorbate 80.
Estonian: Sisaldab: Sukroosi, histidiini, histidiinvesinikkloriidmonohüdraati, polüsorbaat 80.
English: • cold sores (oral herpes)
Estonian: • ohatis (huuleherpes)
English: The frequency of neutropenia in psoriatic arthritis and ankylosing spondylitis is similar to psoriasis.
Estonian: Psoriaatilise artriidi ja anküloseeriva spondüliidi korral oli neutropeenia esinemissagedus sarnane psoriaasi uuringutega.
English: Multipack containing 6 (3 x 2) pre-filled syringes
Estonian: Hulgipakendis 6 (3 x 2) süstlit
English: Syringe guard
Estonian: Süstlikaitsme ääred
English: In both study 3 and study 4, patients randomised to secukinumab received 150 mg or 300 mg doses at weeks 0, 1, 2, 3 and 4, followed by the same dose every month.
Estonian: Nii uuringus 3 kui uuringus 4 said sekukinumabi ravile randomiseeritud patsiendid 150 mg või 300 mg annuseid nädalatel 0, 1, 2, 3 ja 4, millele järgnes sama annuse manustamine kord kuus.
English: Cosentyx 150 mg solution for injection is supplied in a single-use pre-filled pen for individual use.
Estonian: Cosentyx 150 mg süstelahus on saadaval ühekordseks kasutamiseks ette nähtud pen-süstlis.
English: Cosentyx is given via injection under your skin (known as a subcutaneous injection).
Estonian: Cosentyxi manustatakse nahaaluse süstena (subkutaanne süste).
English: Statistically significant improvements (decreases) at week 12 from baseline in the scalp psoriasis study were demonstrated in patient reported signs and symptoms of scalp itching, pain and scaling compared to placebo.
Estonian: Peanaha psoriaasi uuringus näitas sekukinumab võrreldes platseeboga patsiendi poolt kirjeldatud sümptomite - sügelus, valu ja ketendus - statistiliselt olulist paranemist (vähenemine) 12. nädalal.
English: Patients randomised to secukinumab received 10 mg/kg intravenously at weeks 0, 2, and 4, followed by either 75 mg or 150 mg subcutaneously every month starting at week 8.
Estonian: Sekukinumabi rühma randomiseeritud patsiendid said 10 mg/kg veenisiseselt nädalatel 0, 2 ja 4, millele järgnes 75 mg või 150 mg subkutaanne manustamine kord kuus alates 8. nädalast.
English: Cosentyx contains the active substance secukinumab.
Estonian: Cosentyx sisaldab toimeainena sekukinumabi.
English: * Patients treated with secukinumab received 300 mg doses at weeks 0, 1, 2, 3 and 4, followed by the same dose every 4 weeks until week 52.
Estonian: * Sekukinumabiga ravitud patsientidel kasutati 300 mg annust nädalatel 0, 1, 2, 3 ja 4, edaspidi said patsiendid sama annust iga 4 nädala järel kuni nädalani 52.
English: * Patients treated with secukinumab received 300 mg doses at weeks 0, 1, 2 3 and 4, followed by the same dose every 4 weeks until week 52.
Estonian: * Sekukinumabiga ravitud patsientidel kasutati 300 mg annust nädalatel 0, 1, 2, 3 ja 4, edaspidi said patsiendid sama annust iga 4 näda järel kuni nädalani 52.
English: Instructions for use of the Cosentyx SensoReady pen
Estonian: Cosentyx SensoReady pen-süstli kasutusjuhend
English: Otitis externa
Estonian: Väliskõrvapõletik
English: Carefully withdraw slightly more than 1.0 ml of the solution for subcutaneous injection from the vial into a 1 ml graduated disposable syringe using a suitable needle (e.g. 21G x 2″).
Estonian: Tõmmake sobivat nõela (nt 21G x 2″) kasutades viaalist 1 ml skaalajaotusega ühekordselt kasutatavasse süstlasse ettevaatlikult veidi üle 1,0 ml subkutaanset süstelahust.
English: Disposing of your Cosentyx SensoReady pen:
Estonian: Cosentyx SensoReady pen-süstli ära viskamine:
English: • itchy rash (urticaria)
Estonian: • sügelev lööve (urtikaaria)
English: Cosentyx 150 mg solution for injection is supplied in a single-use pre-filled syringe for individual use.
Estonian: Cosentyx 150 mg süstelahus on saadaval ühekordseks kasutamiseks ette nähtud süstlis.
English: Store the pen sealed in its box to protect from light.
Estonian: Pen-süstlit hoida suletuna karbis, valguse eest kaitstult.
English: The single-use vial contains 150 mg secukinumab for reconstitution with sterile water for injections.
Estonian: Ühekordseks kasutamiseks ette nähtud viaal sisaldab 150 mg sekukinumabi lahustamiseks steriilses süstevees.
English: • oral thrush (oral candidiasis)
Estonian: • suusoor (suulimaskesta kandidiaas)
English: Pack containing 1 pre-filled pen
Estonian: Pakendis 1 pen-süstel
English: Store the syringe sealed in its box to protect from light.
Estonian: Süstlit hoida suletuna karbis, valguse eest kaitstult.
English: At week 16, patients who were randomised to placebo at baseline were re-randomised to receive secukinumab (either 75 mg or 150 mg subcutaneously) every month.
Estonian: 16. nädalal randomiseeriti algselt platseeborühma randomiseeritud patsiendid saama sekukinumabi (75 mg või 150 mg subkutaanselt) kord kuus.
English: Multipack containing 6 (3 x 2) pre-filled pens
Estonian: Hulgipakendis 6 (3 x 2) pen-süstlit
English: Secukinumab
Estonian: Sekukinumab
English: Storage of the Cosentyx pre-filled syringe
Estonian: Cosentyx süstli säilitamine
English: Note that foaming of the solution may occur.
Estonian: Lahus võib vahutada.
English: One vial contains 150 mg secukinumab.
Estonian: Üks viaal sisaldab 150 mg sekukinumabi.
English: Caution should be exercised when considering the use of secukinumab in patients with a chronic infection or a history of recurrent infection.
Estonian: Krooniliste või anamneesis korduvate infektsioonidega patsientidel tuleb sekukinumabi kasutamist kaaluda ettevaatusega.
English: Do not use this medicine if you notice that the powder has not fully dissolved or if the liquid contains easily visible particles, is cloudy or is distinctly brown.
Estonian: Mitte kasutada, kui pulber ei ole täielikult lahustunud või vedelik sisaldab kergesti nähtavaid osakesi, on hägune või selgelt pruunikas.
English: Pack containing 2 pre-filled syringes
Estonian: Pakendis 2 süstlit
English: PASI 90 response n (%) 0 (0.0%) 27
Estonian: PASI 90 ravivastus n (%) PASI 100 ravivastus n (%) 0 (0,0%)
English: Multipack: 6 (3 packs of 2) pre-filled syringes
Estonian: Hulgipakend: 6 (3 pakendit, igas 2) süstlit
English: Multipack: 6 (3 packs of 2) pre-filled pens
Estonian: Hulgipakend: 6 (3 pakendit, igas 2) pen-süstlit
English: OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX) - pre-filled pen
Estonian: HULGIPAKENDI VÄLISKARP (KOOS BLUE BOX'iga) - pen-süstel
English: At each timepoint you will receive a 300 mg dose given as two injections of 150 mg.
Estonian: Iga kord manustatakse teile 300-milligrammine annus kahe 150-milligrammise süstena.
English: • Plaque psoriasis
Estonian: • Naastuline psoriaas
English: Patients randomised to secukinumab received 75 mg, 150 mg or 300 mg subcutaneously at weeks 0, 1, 2, 3 and 4, followed by the same dose every month.
Estonian: Sekukinumabi rühma randomiseeritud patsiendid said 75 mg, 150 mg või 300 mg subkutaanselt nädalatel 0, 1, 2, 3 ja 4, millele järgnes sama annuse manustamine kord kuus.
English: The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
Estonian: Soovitatav annus on 300 mg sekukinumabi subkutaanse süstena esialgu nädalatel 0, 1, 2, 3 ja 4, seejärel jätkatakse igakuise säilitusannusega.
English: For other patients, the recommended dose is 150 mg by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
Estonian: Teistele patsientidele on soovitatav annus 150 mg sekukinumabi subkutaanse süstena esialgu nädalatel 0, 1, 2, 3 ja 4, seejärel jätkatakse igakuise säilitusannusega.
English: Store the syringes in the original package in order to protect from light.
Estonian: Süstlid hoida originaalpakendis, valguse eest kaitstult.
English: Patients randomised to secukinumab received 75 mg or 150 mg subcutaneously at weeks 0, 1, 2, 3 and 4, followed by the same dose every month.
Estonian: Sekukinumabi rühma randomiseeritud patsiendid said 75 mg või 150 mg subkutaanselt nädalatel 0, 1, 2, 3 ja 4, millele järgnes sama annuse manustamine kord kuus.
English: Rare (may affect up to 1 in 1,000 people):
Estonian: Harv (võivad tekkida kuni 1 inimesel 1000-st):
English: At week 16, patients who were randomised to placebo at baseline were re-randomised to receive secukinumab (either 150 mg or 300 mg subcutaneously) every month.
Estonian: 16. nädalal randomiseeriti algselt platseeborühma randomiseeritud patsiendid saama sekukinumabi (150 mg või 300 mg subkutaanselt) kord kuus.
English: Patients randomised to placebo who were non-responders at week 16 (early rescue) and other placebo patients at week 24 were crossed over to receive secukinumab (either 75 mg or 150 mg subcutaneously) followed by the same dose every month.
Estonian: Platseeborühma randomiseeritud patsiendid, kes ei olnud 16. nädalaks saavutanud ravivastust (varajane üleminek), ja 24. nädalal teised platseebot saanud patsiendid viidi üle ravile sekukinumabiga (75 mg või 150 mg subkutaanselt), millele järgnes sama annuse manustamine kord kuus.
English: Cosentyx 150 mg powder for solution for injection
Estonian: Cosentyx 150 mg süstelahuse pulber
English: Mean change at
Estonian: Keskmine muutus
English: Number of patients PASI 50 response n (%) 22
Estonian: Patsientide arv PASI 50 ravivastus n (%) PASI 75 ravivastus n (%)
English: Patients randomised to placebo who were non-responders at week 16 (early rescue) and all other placebo patients at week 24 were crossed over to receive secukinumab (either 75 mg or 150 mg subcutaneously), followed by the same dose every month.
Estonian: Platseeborühma randomiseeritud patsiendid, kes ei olnud 16. nädalaks saavutanud ravivastust (varajane üleminek), ja 24. nädalal kõik teised platseebopatsiendid 24. nädalal läksid üle ravile sekukinumabiga (75 mg või 150 mg subkutaanselt), millele järgnes sama annuse manustamine kord kuus.
English: Cosentyx is to be administered by subcutaneous injection.
Estonian: Cosentyxi manustada subkutaanse süstena.
English: OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX) - pre-filled syringe
Estonian: HULGIPAKENDI VÄLISKARP (KOOS BLUE BOX'iga) - süstel
English: Patients randomised to receive placebo who were responders at week 16 were crossed over to receive secukinumab (either 150 mg or 300 mg subcutaneously) at week 24 followed by the same dose every month.
Estonian: Platseeborühma randomiseeritud patsiendid, kes olid 16. nädalaks saavutanud ravivastuse, viidi 24. nädalal üle ravile sekukinumabiga (150 mg või 300 mg subkutaanselt), millele järgnes sama annuse manustamine kord kuus.
English: For the participants completing the diary in each of these studies, statistically significant improvements at week 12 from baseline compared to placebo in patient-reported signs and symptoms of itching, pain and scaling were demonstrated.
Estonian: Mõlemas nimetatud uuringus päevikut täitnud osalejate puhul demonstreeriti patsiendi poolt kirjeldatud sümptomite (sügelus, valu ja ketendus) statistiliselt olulist paranemist ravieelsest 12. nädalal võrreldes platseeboga.
English: The recommended dose is 150 mg by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
Estonian: Soovitatav annus on 150 mg sekukinumabi subkutaanse süstena esialgu nädalatel 0, 1, 2, 3 ja 4, seejärel jätkatakse igakuise säilitusannusega.
English: Pack containing 2 pre-filled pens
Estonian: Pakendis 2 pen-süstlit
English: Patients randomised to secukinumab received 150 mg or 300 mg doses at weeks 0, 1, 2, 3 and 4, followed by the same dose every month.
Estonian: Sekukinumabi rühma randomiseeritud patsiendid said 150 mg või 300 mg annuseid nädalatel 0, 1, 2, 3 ja 4, millele järgnes sama annuse manustamine kord kuus.
English: How to use the Cosentyx pre-filled syringe
Estonian: Kuidas kasutada Cosentyx süstlit
English: Instructions for administration of Cosentyx solution Tilt the vial to an angle of approximately 45° and position the needle tip at the very bottom of the solution in the vial when drawing the solution into the syringe.
Estonian: Kallutage viaali ligikaudu 45° ja lahuse süstlasse tõmbamiseks viige nõela ots viaalis oleva lahuse põhjani.
English: Patients randomised to receive placebo who were non-responders at week 16 (early rescue) were crossed over to receive secukinumab (either 150 mg or 300 mg subcutaneously) at week 16 followed by the same dose every month.
Estonian: Platseeborühma randomiseeritud patsiendid, kes ei olnud 16. nädalaks saavutanud ravivastust (varajane üleminek), viidi 16. nädalal üle ravile sekukinumabiga (150 mg või 300 mg subkutaanselt), millele järgnes sama annuse manustamine kord kuus.
English: Do not use if the liquid contains easily visible particles, is cloudy or is distinctly brown.
Estonian: Ärge kasutage, kui vedelik sisaldab silmaga nähtavaid osakesi, on hägune või tajutavalt pruunikas.
English: All p-values are adjusted for multiplicity of testing based on pre-defined hierarchy at week 24 for PsA study 2, except for ACR70, Dactylitis and Enthesitis, which were exploratory endpoints and all endpoints at week 16.
Estonian: * p<0,05, ** p<0,01, *** p<0,001; võrreldes platseeboga Kõiki p-väärtusi on kohandatud testimise kordsuse järgi eelnevalt kindlaksmääratud hierarhia põhjal 24. nädalal PsA uuringus 2, välja arvatud ACR70, daktüliit ja entesiit, mis olid uurimuslikud tulemusnäitajad, ja kõik tulemusnäitajad 16. nädalal.
English: Cosentyx 150 mg injection secukinumab
Estonian: Cosentyx 150 mg süstelahuse pulber secukinumabum
English: Total score
Estonian: Esmane tulemusnäitaja
English: One pre-filled pen contains 150 mg secukinumab in 1 ml of solution.
Estonian: Üks pen-süstel sisaldab 150 mg sekukinumabi 1 ml-s lahuses.
English: Statistically significant improvements in patient-reported signs and symptoms of itching, pain and scaling at week 16 and week 52 (CLEAR) were demonstrated in the Psoriasis Symptom Diary©
Estonian: toodud patsiendi poolt kirjeldatud sümptomite - sügelus, valu ja ketendus - statistiliselt olulist paranemist.
English: Very common Upper respiratory tract infections Common
Estonian: Ülemiste hingamisteede infektsioonid
English: In AS study 2, among 72 patients initially randomised to secukinumab 150 mg, 61 (84.7%) patients were still on treatment at week 52.
Estonian: AS uuringus 2 said 52. nädalal endiselt ravi 61 (84,7%) patsienti 72-st, kes randomiseeriti algselt saama sekukinumabi 150 mg. 72-st sekukinumabi 150 mg rühma randomiseeritud patsientidest 45 ja 35 saavutasid vastavalt ASAS 20/40 ravivastuse.
English: One pre-filled syringe contains 150 mg secukinumab in 1 ml of solution.
Estonian: Üks süstel sisaldab 150 mg sekukinumabi 1 ml-s lahuses.
English: Be careful not to touch the syringe guard wings before use.
Estonian: Enne kasutamist vältige puutumist vastu süstlikaitsme ääri.
English: Placebo (n=245)
Estonian: Sekukinumab 300 mg (n=245) Platseebo (n=245)
English: Store the pens in the original package in order to protect from light.
Estonian: Pen-süstlid hoida originaalpakendis, valguse eest kaitstult.
English: Each vial of powder contains 150 mg secukinumab.
Estonian: Üks pulbri viaal sisaldab 150 mg sekukinumabi (secukinumabum).
English: Instructions for use of Cosentyx pre-filled syringe
Estonian: Cosentyx süstelahuse pulbri kasutusjuhend
English: Histidine hydrochloride monohydrate Methionine
Estonian: Histidiinvesinikkloriidmonohüdraat Metioniin
English: Cosentyx 150 mg powder for solution for injection secukinumab
Estonian: Cosentyx 150 mg süstelahuse pulber secukinumabum s.c.
English: Cosentyx 150 mg solution for injection in pre-filled syringe secukinumab
Estonian: Cosentyx 150 mg süstelahus süstlis sekukinumab (secukinumabum)
English: Each pre-filled syringe contains 150 mg secukinumab.
Estonian: Üks süstelahuse pulbri viaal sisaldab 150 mg sekukinumabi.
English: Keep the pre-filled pens in the outer carton in order to protect from light.
Estonian: Hoida pen-süstlid välispakendis, valguse eest kaitstult.
English: Number of patients with ≥3% BSA psoriasis skin involvement at baseline
Estonian: Patsientide arv, kellel oli ravieelselt psoriaasist haaratud 3% kehapinna suurusest PASI 75 ravivastus n (%)
English: In the TRANSFIGURE study, secukinumab was superior to placebo at week 16 (46.1% for 300 mg, 38.4% for 150 mg and 11.7% for placebo) as assessed by significant improvement from baseline in the Nail Psoriasis Severity Index (NAPSI %) for patients with moderate to severe plaque psoriasis with nail involvement.
Estonian: TRANSFIGURE uuringus mõõduka kuni raske naastulise psoriaasiga patsientidel, kellel olid haigusest haaratud ka küüned, hinnati olulist paranemist küünepsoriaasi tõsiduse indeksis (Nail Psoriasis Severity Index, NAPSI %) võrreldes ravieelsega ning 16. nädalal näitas sekukinumab paremust võrreldes platseeboga (46,1% 300 mg korral, 38,4% 150 mg korral ja 11,7% platseebo korral).
English: PEN LABEL
Estonian: PEN-SÜSTLI ETIKETT
English: 150 mg secukinumab.
Estonian: Cosentyx 150 mg süstevedelik secukinumabum s.c.
English: Each pre-filled pen contains 150 mg secukinumab.
Estonian: Üks pen-süstel sisaldab 150 mg sekukinumabi.
English: Cosentyx 150 mg
Estonian: Cosentyx 150 mg süstelahus süstlis
English: Please read the instructions before use
Estonian: Palun lugege juhiseid enne kasutamist
English: Do not place fingers on the windows.
Estonian: Ärge pange sõrmi aknale.
English: Ask your pharmacist how to throw away medicines you no longer use.
Estonian: Küsige oma apteekrilt, kuidas visata ära ravimeid, mida mida te enam ei kasuta.
English: Therefore, this information is not
Estonian: Seepärast pole see informatsioon
English: Data were as follows (values in brackets show the 95% confidence intervals):
Estonian: Andmed olid alljärgnevad (sulgudes olevad väärtused näitavad 95%-st usaldusintervalli):
English: - Headache and muscular pain.
Estonian: - Peavalu ja lihasevalu.
English: The use of IDflu should be based on official recommendations.
Estonian: IDflu kasutamine peab põhinema ametlikel soovitustel.
English: Seroprotection is generally obtained within 2 to 3 weeks.
Estonian: Seroprotektsioon omandatakse üldiselt 2 kuni 3 nädala vältel.
English: You should see your doctor immediately if you experience symptoms of angioedema, such as:
Estonian: Peaksite kohe pöörduma oma arsti poole, kui kogete angioödeemi sümptomeid, nagu:
English: Orient the needle away from you and others.
Estonian: Suunake nõel endast ja teistest eemale.
English: See also section 3.
Estonian: Vt ka lõik 3.
English: (immunosuppression) due to disease or medicines, because the vaccine may not work very well in this case.
Estonian: (immuunsupressioon) haiguse või ravimite tõttu, kuna vaktsiin võib sellisel juhul mitte piisavalt hästi töötada.
English: Date of latest renewal: 24 February 2014
Estonian: Müügiloa viimase uuendamise kuupäev: 24. veebruar 2014
English: The recommended site of administration is the region of the deltoid.
Estonian: Soovitatud manustamiskoht on deltalihase piirkond.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 24 February 2009
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE /MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 24. veebruar 2009
English: Always use this vaccine exactly as your doctor or pharmacist has told you.
Estonian: Kasutage seda vaktsiini alati täpselt nii, nagu arst või apteeker on teile selgitanud.
English: Interference with serological testing: See section 4.5.
Estonian: Seroloogilise testimise häire: vt. lõik 4.5.
English: The vaccine was immunogenic in mice and rabbits.
Estonian: Vaktsiin oli immunogeenne hiirtel ja küülikutel.
English: Justification for not including Braille is accepted.
Estonian: INFORMATSIOON BRAILLE'I KIRJAS Põhjendus Braille mitte lisamiseks on aktsepteeritud.
English: Finger pads
Estonian: Sõrme padjandid
English: - If, for any reason, you have a blood test within a few days following an influenza vaccination, please tell your doctor.
Estonian: - Kui teile tehakse vereanalüüs mõni päev pärast gripivaktsiini saamist, teavitage palun sellest oma arsti.
English: IDflu is not recommended for use in children and adolescents below 18 years due to insufficient data on safety and efficacy.
Estonian: IDflu'd ei soovitata kasutada alla 18-aastastel lastel ja noorukitel ohutuse ja efektiivsuse andmete puudumise tõttu.
English: Children and adolescents IDflu is not recommended for use in children and adolescents below 18 years.
Estonian: Lapsed ja noorukid IDflu'd ei soovitata kasutada lastel ja alla 18-aastastel noorukitel.